Abstract Objective To evaluate the clinical features, laboratory findings, diagnosis and treatment, and prognosis of children with systemic lupus erythematosus (SLE) accompanied by pulmonary hypertension (PH). Methods The clinical symptoms, laboratory findings, echocardiographic features, SLE disease activity index, and treatment outcome of 15 hospitalized children with SLE accompanied by PH were retrospectively analyzed. Results Among the 15 patients, the median interval from diagnosis of SLE to diagnosis of PH was 0.1 year (range:0-6.5 years). Aside from PH-related symptoms, Raynaud's phenomenon was observed in 6 (40%) of the 15 patients. There was no significant difference in SLE disease activity (evaluated by complements 3 and 4 levels, erythrocyte sedimentation rate, and positive rate of anti-double-stranded DNA) between patients with mild-to-moderate PH and those with severe PH (P < 0.05). As for treatment, 13 patients received immunosuppressive therapy with glucocorticoids, and among them 2 patients received PH-targeted therapy. During a median follow-up of 8.0 years (range:0.5-18.1 years) since the diagnosis of PH, 2 deaths were noted with class III or IV cardiac function (World Health Organization), while the other patients were in a stable condition. Conclusions Raynaud's phenomenon is a common clinical manifestation in children with SLE accompanied by pulmonary hypertension (PH). PH severity is not significantly associated with SLE disease activity, and thus greater focus should be placed upon early screening of pulmonary arterial pressure in SLE patients. Early diagnosis and early treatment can improve the prognosis of children with SLE.
LI Ji,MA Jing-Ran,SUN Zhi-Xing et al. A clinical analysis of 15 children with systemic lupus erythematosus accompanied by pulmonary hypertension[J]. CJCP, 2017, 19(6): 658-662.
LI Ji,MA Jing-Ran,SUN Zhi-Xing et al. A clinical analysis of 15 children with systemic lupus erythematosus accompanied by pulmonary hypertension[J]. CJCP, 2017, 19(6): 658-662.
Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension[J]. J Am Coll Cardiol, 2013, 62(25 Suppl):D42-D50.
[2]
Ruiz-Irastorza G, Garmendia M, Villar I, et al. Pulmonary hypertension in systemic lupus erythematosus:prevalence, predictors and diagnostic strategy[J]. Autoimmun Rev, 2013, 12(3):410-415.
[3]
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40(9):1725.
[4]
Cossío-Aranda J, Zamora KD, Nanda NC, et al. Echocardiographic correlates of severe pulmonary hypertension in adult patients with ostium secundum atrial septal defect[J]. Echocardiography, 2016, 33(12):1891-1896.
[5]
Konstantinides S, Geibel A, Olschewski M, et al. A comparison of surgical and medical therapy for atrial septal defect in adults[J]. N Engl J Med, 1995, 333(8):469-473.
[6]
Xia YK, Tu SH, Hu YH, et al. Pulmonary hypertension in systemic lupus erythematosus:a systematic review and analysis of 642 cases in Chinese population[J]. Rheumatol Int, 2013, 33(5):1211-1217.
[7]
Li M, Wang Q, Zhao J, et al. Chinese SLE Treatment and Research group (CSTAR) registry:II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus[J]. Lupus, 2014, 23(10):1085-1091.
Anuardo P, Verdier M, Gormezano NW, et al. Subclinical pulmonary in childhood systemic lupus erythematosus associated with minor disease manifestations[J]. Pediatr Cardiol, 2017, 38(2):234-239.
Fei Y, Shi X, Gan F, et al. Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years[J]. Clin Rheumatol, 2014, 33(1):57-63.
[13]
Huang C, Li M, Liu Y, et al. Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients[J]. Medicine (Baltimore), 2016, 95(10):e2761.
[14]
Kasparian A, Floros A, Gialafos E, et al. Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus[J]. Lupus, 2007, 16(7):505-508.
[15]
Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension[J]. Chest, 2012, 141(1):210-221.
[16]
Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling[J]. J Am Coll Cardiol, 2009, 54(1 Suppl):S10-S19.
[17]
Akdogan A, Kilic L, Dogan I, et al. Pulmonary hypertension in systemic lupus erythematosus:pulmonary thromboembolism is the leading cause[J]. J Clin Rheumatol, 2013, 19(8):421-425.
[18]
Takatsuki S, Soep JB, Calderbank M, et al. Connective tissue disease presenting with signs and symptoms of pulmonary hypertension in children[J]. Pediatr Cardiol, 2011, 32(6):828-833.
[19]
Huggins JL, Holland MJ, Brunner HI. Organ involvement other than lupus nephritis in childhood-onset systemic lupus erythematosus[J]. Lupus, 2016, 25(8):857-863.
[20]
Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension[J]. Rev Esp Cardiol (Engl Ed), 2016, 69(2):177.
[21]
Kommireddy S, Bhyravavajhala S, Kurimeti K, et al. Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy:an observational study[J]. Rheumatology (Oxford), 2015, 54(9):1673-1679.
[22]
Prabu A, Gordon C. Pulmonary arterial hypertension in SLE:what do we know?[J]. Lupus, 2013, 22(12):1274-1285.
[23]
Sitbon O, Jaïs X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension:a pilot study[J]. Eur Respir J, 2014, 43(6):1691-1697.
[24]
Galiè N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study):a double-blind, randomised controlled trial[J]. Lancet, 2008, 371(9630):2093-2100.
[25]
Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension[J]. N Engl J Med, 2002, 346(12):896-903.
[26]
Chow SL, Chandran V, Fazelzad R, et al. Prognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension[J]. Lupus, 2012, 21(4):353-364.
